BRAF and colorectal carcinoma: SHP-2 contribution was next analyzed in established human CRC cell lines, namely DLD-1 and SW480 which exhibit an activating mutation in the KRAS gene, and in HT-29 cells which have an activating BRAF mutation (Figure 3A).